[1] 中华医学会肝病学分会. 肝硬化诊治指南. 中华肝脏病杂志, 2019, 27: 846-865.
[2] Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 2017, 390: 1151-1210.
[3] Fernández J, Prado V, Trebicka J, et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. J Hepatol, 2019, 70: 398-411.
[4] Hsu YC, Yang YY, Tsai IT. Lymphocyte-to-monocyte ratio predicts mortality in cirrhotic patients with septic shock. Am J Emerg Med, 2021, 40:70-76.
[5] Basho K, Zoldan K, Schultheiss M, et al. IL-2 contributes to cirrhosis-associated immune dysfunction by impairing follicular T helper cells in advanced cirrhosis. J Hepatol, 2021, 74: 649-660.
[6] Lebossé F, Gudd C, Tunc E, et al. CD8(+)T cells from patients with cirrhosis display a phenotype that may contribute to cirrhosis-associated immune dysfunction. EBioMedicine, 2019, 49:258-268.
[7] Tuchendler E, Tuchendler PK, Madej G. Immunodeficiency caused by cirrhosis. Clin Exp Hepatol, 2018, 4: 158-164.
[8] Abbas AK, Trotta E, R Simeonov D, et al. Revisiting IL-2: biology and therapeutic prospects. Sci Immunol,2018, 3:eaat1482.
[9] Wu T, Shin HM, Moseman EA, et al. TCF1 is required for the T follicular helper cell response to viral infection. Cell Rep, 2015, 12: 2099-2110.
[10] Dirchwolf M, Podhorzer A, Marino M, et al. Immune dysfunction in cirrhosis: distinct cytokines phenotypes according to cirrhosis severity. Cytokine, 2016, 77:14-25.
[11] Mouillaux J, Allam C, Gossez M, et al. TCR activation mimics CD127lowPD-1highphenotype and functional alterations of T lymphocytes from septic shock patients. Crit Care,2019, 23: 131.
[12] Tripathi A, Debelius J, Brenner DA, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol,2018, 15: 397-411.
[13] Solé C, Guilly S, Da Silva K, et al. Alterations in gut microbiome in cirrhosis as assessed by quantitative metagenomics: relationship with acute-on-chronic liver failure and prognosis. Gastroenterology, 2021, 160: 206-218.
[14] Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol, 2014, 60: 1310-1324.
[15] Trebicka J, Reiberger T, Laleman W. Gut-Liver axis links portal hypertension to acute-on-chronic liver failure. Visc Med, 2018, 34: 270-275.
[16] Tripathi DM, Vilaseca M, Lafoz E, et al. Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension. Gastroenterology, 2018, 155: 1564-1577.
[17] Hackstein CP, Assmus LM, Welz M, et al. Gut microbial translocation corrupts myeloid cell function to control bacterial infection during liver cirrhosis. Gut, 2017, 66: 507-518.
[18] Asanoma M, Ikemoto T, Mori H, et al. Cytokine expression in spleen affects progression of liver cirrhosis through liver-spleen cross-talk. Hepatol Res, 2014, 44: 1217-1223.
[19] Ren S, Zhang S, Li M, et al. NF-κB p65 and c-Rel subunits promote phagocytosis and cytokine secretion by splenic macrophages in cirrhotic patients with hypersplenism. Int J Biochem Cell Biol, 2013, 45: 335-343.
[20] Jiang A, Zhang S, Li Z, et al. miR-615-3p promotes the phagocytic capacity of splenic macrophages by targeting ligand-dependent nuclear receptor corepressor in cirrhosis-related portal hypertension. Exp Biol Med, 2011, 236: 672-680.
[21] Fair KA, Connelly CR, Hart KD, et al. Splenectomy is associated with higher infection and pneumonia rates among trauma laparotomy patients. Am J Surg, 2017, 213: 856-861.
[22] Nomura Y, Kage M, Ogata T, et al. Influence of splenectomy in patients with liver cirrhosis and hypersplenism. Hepatol Res, 2014, 44: E100-109.
[23] 纪泛扑, 黄娜, 张澍,等. 脾切除对丙型病毒性肝炎后肝硬化门静脉高压症患者细胞免疫功能的影响. 中华肝脏外科手术学电子杂志, 2015, 4: 232-236.
[24] Rosenblatt R, Atteberry P, Tafesh Z, et al. Uncontrolled diabetes mellitus increases risk of infection in patients with advanced cirrhosis. Dig Liver Dis, 2021, 53: 445-451.
[25] Elkrief L, Chouinard P, Bendersky N, et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology, 2014, 60: 823-831.
[26] Bernardi M, Angeli P, Claria J, et al. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut,2020, 69: 1127-1138. |
